Skip to main content
SpringerLink
Log in

La chimiothérapie et l’hormonothérapie peuvent-elles être plus graves que la maladie?

Chemotherapy and endocrine therapy can they be worse than disease?

  • Conference paper
Cancer du sein : surdiagnostic, surtraitement

  • 223 Accesses

Résumé

Quels sont les inconvénients des traitements face à leurs bénéfices possibles dans les cancers à risque intermédiaire? Mais aussi dans l’information avantages/risques que nous devons à toute patiente? Comment emplit-on ces plateaux (contenu et présentation de l’information) et qui apprécie de quel côté la balance penchera?

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Shanley S, McReynolds K, Ardem-Jones A et al. (2006) Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom. Clin Cancer Res 12: 7033–7038

    Article  PubMed  CAS  Google Scholar 

  2. Lyman GH, Michels SL, Reynolds MW et al. 2010 Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 116: 5555–5563

    Article  PubMed  Google Scholar 

  3. Miteva M, Misciali C, Fanti PA et al. 2011 Permanent alopecia after systemic chemotherapy: a clinicalpathological study of 10 cases. Am J Dermatopathol 33: 345–350

    Article  PubMed  Google Scholar 

  4. Chlebowski RT, Blackburn GL, Thomson CA et al. 2006 Dietary fat reduction and breast cancer outcome interim efficacy results from the Women’s Intervention Nutrition Study. J Natl Cancer Inst 98: 1767–1776

    Article  PubMed  Google Scholar 

  5. Alfano CM, Lichstein KL, Vander Wal GS et al. 2011 Sleep duration change across breast cancer survivorship: associations with symptoms and health-related quality of life. Breast Cancer Res Treat (in press)

    Google Scholar 

  6. Ahles TA, Saykin AJ, Furstenberg CT et al. (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long term survivors of breast cancer and lymphoma. J Clin Oncol 20: 485–493

    Article  PubMed  CAS  Google Scholar 

  7. Fu AZ, Chen L, Sullivan SD et al. 2011 Absenteism and short-term disability associated with breast cancer. Breast Cancer Res Treat (in press)

    Google Scholar 

  8. DiCarlo I, Pulvirenti E, Mamimo M et al. (2010) Increased use of percutaneus technique for totally implantable venous access devices. Is it real progress? A 27-year comprehensive review of early complications. Ann Surg Oncol 17: 1649–1656

    Article  Google Scholar 

  9. Azim HA, de Azambuja E, Colozza M et al. 2011 Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol (in press)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Département de sénologie, Centre Oscar Lambret, 3, rue Frédéric-Combemale, 59020, Lille

    S. Giard

Authors
  1. S. Giard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag France, Paris

About this paper

Cite this paper

Giard, S. (2012). La chimiothérapie et l’hormonothérapie peuvent-elles être plus graves que la maladie?. In: Cancer du sein : surdiagnostic, surtraitement. Springer, Paris. https://doi.org/10.1007/978-2-8178-0249-7_31

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0249-7_31

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0248-0

  • Online ISBN: 978-2-8178-0249-7

Publish with us

Policies and ethics

Search

Navigation